[Allogenic stem cell transplantation after non-myeloablative conditioning regimen (mini-allogenic" stem cell transplantation)].
Allogeneic stem cell transplantation is able to cure many hematologic malignancies, through, at least partially, a graft versus disease effect of the donor's immune system transfer. However, the toxicity of this technique limits its use to selected patients. The aim of non-myeloablative stem cell transplantation is to reduce the toxicity of the conditioning regimen while allowing the engrafement of donor's stem cells and the immunological antitumoral activity of the donor's immune system. Several reports have already demonstrated the validity of this concept. This new multi-step therapeutic strategy is complex, raises many questions and deserves further studies to be fully applicable to a greater number of patients.
Milpied
N
N
Service d'hématologie, CHU de Nantes-Hôtel Dieu, place Alexis Ricordeau, BP 1005, 44035 Nantes, France. nmilpied@chu-nantes.fr
D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D011687:Purines / Q000627:therapeutic use; D014019:Tissue Donors; D014184:Transplantation, Homologous / Q000276:immunology
D011687:Purines